PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Attorney Docket No: Q92644

Scott GAYNOR et al. Confirmation No.: 1924

Application No.: 10/579,341 Group Art Unit: 1621

Filed: August 24, 2006 Examiner: Clinton A Brooks

For: CROSSLINKABLE ARYLAMINE COMPOUNDS AND CONJUGATED

OLIGOMERS OF POLYMERS BASED THEREON

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir.

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO/SB/08 (modified) which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of the listed documents, except U.S. patents, publications and/or co-pending non-provisional applications, is submitted herewith.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicants also enclose herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents (Taiwanese Office Action dated June 30, 2011 (accompanied by an English translation of at least the relevant portion thereof)), indicating the degree of relevance found by the foreign patent office. In addition, Applicants point out that U.S. Patent No. 6.287,713 corresponds to TW 419929.

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

U.S. Application No. 10/579,341 (Attorney Docket No. Q92644)

The present Information Disclosure Statement is being filed after the later of three

months from the application's filing date and the mailing date of the first Office Action on the

merits, but before a final Office Action. Therefore, Applicants are filing concurrently herewith a

Statement Under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicants do not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The U.S. Patent and Trademark Office is hereby directed and authorized to charge all

required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880.

Please also credit any overpayments to said Deposit Account.

Respectfully submitted, / Michael G. Raucci /

Michael G. Raucci Registration No. 61,444

SUGHRUE MION, PLLC Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: August 11, 2011

MODIFIED PTO/SB/08a (01-10)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

	Approved for use infought 07/3 frzo 12.
Application Number	10/579,341
Confirmation Number	1924
Filing Date	August 24, 2006
First Named Inventor	Scott GAYNOR
Art Unit	1621
Examiner Name	Clinton A BROOKS
Attorney Docket Number	092644

CERTIFICATION STATEMENT

Diagea eaa	27	CER	10	7 and	4 (26 +0	maka	the	annmnris	ıta :	ealaction/s	٠١٠

PIE	Please see 37 CFR 1.97 and 1.36 to make the appropriate selection(s).					
☑	That each item of information contained in the Information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).					
OF	R					
0	That no item of information contained in the Information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).					
	That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application, and that the communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of said Information Disclosure Statement. See 37 CFR 1.704(d).					
	Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.					
Ø	The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.					
	None					
WASHINGTON OFFICE						
	23373					
	CUSTOMER NUMBER					
SIGNATURE						
la:	A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d)					

for the form of the signature

Signature	/ Michael G. Raucci /	Date (YYYY-MM-DD)	2011-08-11
Name/Print	Michael G. Raucci	Registration Number	61,444

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard Today and Course of USFT or fating Documents as www.com/ 100000 of interface of the appropriate symbols as includated on the document of the part of the regin of the Emperor must precede the serial number of the patient document. 4 Kind of document by the appropriate symbols as includated on the document under WIPO Standard ST.16 if possible, 5 Applicant is to place a check mark here if English language translation is attached.